A cerebrospinal fluid biosignature for the diagnosis of Alzheimer’s disease

Barichello, Tatiana; Giridharan, Vijayasree V.; Dal‐Pizzol, Felipe

doi:10.1590/1516-4446-2019-0629

Cited by 8 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Propionate acid can contribute to immune homeostasis by regulating cellular subpopulations ( Dupraz et al, 2021 ). Butyric acid provides sufficient energy for intestinal epithelial cells and alternative substrates for brain metabolism and upregulates the expression of tight junction proteins to enhance the integrity of the BBB ( Barichello et al, 2019 ; Silva et al, 2020 ; Chen et al, 2022 ). In addition, SCFAs clear protein aggregates in the brain by enhancing the function of microglia ( Erny et al, 2015 ; Wenzel et al, 2020 ).…”

Section: Crosstalk Between the Peripheral And Central Systems And Alt...mentioning

confidence: 99%

The potential of the gut microbiome for identifying Alzheimer’s disease diagnostic biomarkers and future therapies

Zhan¹,

Al‐Nusaif²,

Ding³

et al. 2023

Front. Neurosci.

View full text Add to dashboard Cite

Being isolated from the peripheral system by the blood–brain barrier, the brain has long been considered a completely impervious tissue. However, recent findings show that the gut microbiome (GM) influences gastrointestinal and brain disorders such as Alzheimer’s disease (AD). Despite several hypotheses, such as neuroinflammation, tau hyperphosphorylation, amyloid plaques, neurofibrillary tangles, and oxidative stress, being proposed to explain the origin and progression of AD, the pathogenesis remains incompletely understood. Epigenetic, molecular, and pathological studies suggest that GM influences AD development and have endeavored to find predictive, sensitive, non-invasive, and accurate biomarkers for early disease diagnosis and monitoring of progression. Given the growing interest in the involvement of GM in AD, current research endeavors to identify prospective gut biomarkers for both preclinical and clinical diagnoses, as well as targeted therapy techniques. Here, we discuss the most recent findings on gut changes in AD, microbiome-based biomarkers, prospective clinical diagnostic uses, and targeted therapy approaches. Furthermore, we addressed herbal components, which could provide a new venue for AD diagnostic and therapy research.

show abstract

Section: Crosstalk Between the Peripheral And Central Systems And Alt...mentioning

confidence: 99%

The potential of the gut microbiome for identifying Alzheimer’s disease diagnostic biomarkers and future therapies

Zhan¹,

Al‐Nusaif²,

Ding³

et al. 2023

Front. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Further, for measuring neurodegeneration, the major biomarkers utilised are t-Tau, p-Tau, glucose hypometabolism (FDG-PET) and atrophy in structural MRI, which corelates clinically with elevated NFT levels and neuronal losses (Jack & Holtzman, 2013). Also, a low Aβ 1-42 and the Aβ 1-42 /Aβ 1-40 ratio, as well as high levels of Growth-Associated Protein 43 (GAP-43), p-Tau 181 , p-Tau 217 , and NfL, are considerably reliable CSF biomarkers for early AD diagnosis (Barichello et al, 2019). Mostly the p-tau CSF levels are noticeably elevated in individuals with MCI and is also regarded as the most reliable biomarker for onset of neuronal degeneration.…”

Section: Progression and Early Diagnostic Role Of Biomarkers In Admentioning

confidence: 99%

“…By the time AD is clinically diagnosed, neuronal loss and neuropathologic abnormalities develop across different brain regions. As a result, emerging research circles are concentrating on asymptomatic patients or persons with cognitive health who have significant indicators of AD present in their biofluids such CSF and blood (Barichello et al, 2019; Xu et al, 2021) (Figure 2).…”

Section: Progression and Early Diagnostic Role Of Biomarkers In Admentioning

confidence: 99%

Alzheimer's disease: A role of biomarkers in early diagnosis and evidences from African ethnomedicinal knowledge

Balkrishna

Verma

Singh

et al. 2023

Eur J of Neuroscience

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a neurological ailment that primarily affects the elderly and necessitates an efficient treatment regimen backed up by extensive care. Despite advancement in the in vivo imaging techniques focussing on early diagnosis of reliable biomarkers using novel magnetic resonance imaging (MRI) and positron emission topography (PET) scans, AD remains largely unexplained and effective preventative and treatment strategies are still lacking. Consequently, research groups are constantly attempting to improve its early detection, using both invasive and non‐invasive techniques with established core markers like Aβ and Tau (t‐tau and p‐tau) proteins. Unfortunately, African American and other black races are facing an increasing burden of closely associated risk factors, and only a few attempts have been made to find effective complementary and alternative therapies for AD cure and management. A greater epidemiology and natural product research are required to deal with the concurrent rise of dementia among quickly ageing African population, which so far have largely been ignored in addition to a disparity in the AD risk factors. We have tried to bring attention to the issue by reviewing up on this predisposition while generating a perspective on how race may affect AD risk and expression. This article also puts emphasis on finding new research leads from African phytodiversity while presenting several of the important species along with their biological agents found helpful in dementia related symptoms.

show abstract

“…The established CSF biomarkers for Alzheimer disease diagnosis include low levels of Aβ 1-42 and the Aβ 1-42 /Aβ 1-40 ratio, increased levels of T-Tau, P-Tau, NFL, P-Tau181, P-Tau217, and growth-associated protein 43 (GAP-43). 4 Alzheimer disease triggers an accumulation of Aβ 1-42 in the brain and, as a consequence, Aβ 1-42 levels decrease in the CSF and bloodstream. CSF levels of T-tau and P-tau are elevated due to cortical neuronal loss and cortical tangle formation, respectively, while increased NFL levels are associated with neuroaxonal damage.…”

mentioning

confidence: 99%